Clinical Trial Update: Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a CD25 monoclonal antibody–containing GVHD prophylaxis to reduce severe acute GVHD after umbilical cord blood transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Malignant Hematologic Neoplasm

Drugs mentioned

• CD25 monoclonal antibody–containing GVHD prophylaxis (CD25 monoclonal antibody)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm | Phase 2 | Status: NOT_YET_RECRUITING